A case of polyarteritis is reported in an 18-year old woman, occurring 2 years after an allogeneic bone marrow transplant. The clinical manifestations were similar to those of polyarteritis nodosa (PAN) with a wide range of organs involved including life-threatening cardiac and mesenteric problems requiring plasmapheresis and intravenous immunoglobulin (IgIV).
Chronic GVHD is a frequent complication following bone marrow transplantation (BMT). Most of the clinical manifestations are similar to those observed in collagen vascular diseases such as scleroderma or Sjögren's syndrome. 1 This is the case of a patient who developed a severe and widespread vasculopathy with a clinical course resembling PAN, 2 years after an allogenic BMT, despite conventional immunosuppressive therapy for cutaneous and liver cGVHD. The patient improved dramatically with pulses of methylprednisolone, used as front line therapy with IgIV and plasma exchanges (PE). To the best of our knowledge, this complication has never been previously reported as manifestation of cGvHD.
Case report
A 16-year-old girl was referred to our institution in January 1996 with M2 acute myeloid leukemia. Complete remission was achieved after the first course of conventional chemotherapy. A genoidentical allogeneic BMT from her healthy sister was performed as consolidation treatment. Conditioning was with TBI (12 Gy in six fractions over 3 days) and cyclophosphamide (120 mg/kg over 2 days). Acute GVHD prophylaxis was with methotrexate and CsA. Her post-BMT period was complicated by stage 3 acute cutaneous GVHD (day +34), successfully treated with prednisolone. At day +69, CsA was discontinued due to CNS toxicity and was not replaced by any other agent. Later, the patient developed chronic skin (treated with steroids and puvatherapy) and liver GVHD (day +270, presenting as anicteric cholestasis without no evidence of EBV, parvovirus B19, hepatitis B or C viruses involvement). Hepatitis G virus RNA, CMV antigenemia and CMV RNA in the urine were noted, but these viruses had no histological impact on liver biopsies. At day +300, the patient developed visual impairment due to central retinal vein occlusion.
No predisposition to thrombosis was documented, screening for antithrombin III (ATIII), C and S protein deficiencies and factor V Leyden being negative. At day +600, spreading and worsening of the ischemic syndrome occurred associated with abdominal pain, diarrhea and weight loss related to thrombosis of the inferior mesenteric artery (arteriography also showed narrow hepatic and mesenteric arteries without pseudo-aneurysm). There was no associated depression in the blood count and thus a bone marrow aspirate was not performed, neither was an assessment for paroxysmal nocturnal hemoglobinuria or deficiency in GPI-anchored proteins undertaken. C reactive protein was elevated to 250 mg/l secondary to the inflammation.
Concomitantly, myocardial infarction was documented on coronary arteriography and scintiography after ST segment elevation had been noted. The patient also had a painful soft tissue swelling of the left shoulder. Muscle biopsy revealed severe myogenic problems, with a lympho-histiocytic infiltrate, plasma cell and eosinophilia, associated with angiitis, but neither fasciitis nor typical necrotizing lesions were present.
Again, there was no evidence of immune dysfunction or a thrombosis-enhancing condition (antiphospholipid antibodies were negative, as were antineutrophil cytoplasm antibodies and antibodies to nuclei and DNA). There were no smooth muscle or anti-cardiolipid antibodies, no cryoglobulinemia, normal complement fractions, AT III, C and S protein levels. Circulating immune complexes were present. There was no evidence of thrombotic microangiopathy, renal or lung impairment (creatinine clearance ϭ 120 ml/min). Microscopic examination of the urine nevertheless documented leucocytes Ͼ7 ϫ 10 4 /ml. At the onset, IgIV (2 g/kg), pulses of methylprednisolone (5 mg/kg/day 3 days then rapid tapering), azathioprine (50 mg daily) were initiated, and the following month PE were given (26 over a 2 1 2 month period). Pain rapidly improved, there was reduced hepatic disturbance and inflammatory proteins, and steroids were tapered to their lowest level (1 mg/day). Over the following weeks, maintenance therapy using azathioprine (25 mg daily) and IgIV (15 g per week) was added to the low dose steroids to reduce the risk of relapse. Exacerbations in the abdominal angina still occurred for about 1 year after PE, but 'short' steroid therapy was always effective for pain and weight loss.
At day +720 vasculitic skin lesions also appeared on the fingers, but capillaroscopy was non-contributary. Skin biopsy was not performed at this time.
At 66 months post-BMT, the patient remains in CR with full chimerism and chronic cutaneous and liver GVHD, and the ischemic cardiopathy has become increasingly detrimental to organ function.
Weekly immunoglobulin, infusions azathioprine 25 mg per day and a 5 mg daily dose of steroids allow relief of the abdominal pain and oral nutrition. There have been no other vasculitic manifestations.
Discussion
This kind of polyangiitis in the post-BMT setting has never been reported before. Its symptoms were spread over a 1 1 2 year time period, and had features similar to those of PAN.
Even if the etiology of PAN remains unknown, an early history of CMV infection, CMV-related PAN having been described in non-hematologic patients, and detection of CIC may suggest this diagnosis in our patient since classic PAN has been described as occurring shortly after infections, and is thought to be immune complex-mediated. However, hepatitis G virus is unlikely to play a role in the vasculitides, since RNA is not usually found in the lesions of this type of patient. 2 The other similarities with PAN were: five out of 10 PAN 1990 classification criteria were fulfilled: myalgia, weight loss, skin vasculitides, arteriographic abnormalities and mononeuropathy. 3 The Chapel Hill 1992 consensus conference criteria for PAN (negative pANCA and no small-sized vessel infiltration) were also found, excluding the diagnosis of microscopic polyangiitis. 4 An antiphospholipid syndrome has already been described in a patient suffering from cGVHD, 5 but in our case antiphospholipid antibodies were not detected.
On the other hand, some events seen in our patient were not part of classic PAN, ie coronary arteriography was abnormal and correlated with signs of myocardial ischemia unlike the situation in the PAN population with cardiac involvement. No pseudo-aneurysms were detected, no renal impairment was observed and relapses after potent first line treatment were common, despite the use of immunosuppression.
The prognosis is poor in HBV-negative PAN patients with myocardial or digestive tract involvement. Even in these cases, PE are not indicated, except in relapsing or refractory forms of the condition, or when there is kidney damage. 6 In our patient, in spite of these life-threatening problems, the benefits were impressive when PE were added to pulses of methylprednisolone, IgIV and azathioprine.
In conclusion, this polyvisceral vasculitis displayed many features mimicking PAN, even though the clinical and biological presentations of the vasculitis were less clear than in individuals outside the BMT setting. There has never been any suggestion of another thrombosis-enhancing condition, which dramatically improves with potent therapy including PE. In particular, we found no evidence for Kawasaki disease in the 12-year-old donor, nor did we discover a family history of thromboembolism.
Despite treatment, exacerbations occurred when the steroids were tapered, surely reflecting disease activity in the context of cGVHD.
